Premium
Exposure to bisphosphonates and risk of colorectal cancer
Author(s) -
Ma Jingjing,
Gao Sheng,
Ni Xiaojian,
Chen Fei,
Liu Xiaofeng,
Xie Hui,
Yin Hong,
Lu Cheng
Publication year - 2013
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12105
Subject(s) - medicine , colorectal cancer , relative risk , confidence interval , odds ratio , meta analysis , publication bias , cohort study , oncology , cancer
Animal and in vitro studies suggest that the use of bisphosphonates ( BP s) may be associated with reduced risk for colorectal cancer ( CRC ). However, results from these studies have been inconsistent. The aim of our study was to review and summarize the evidence provided by longitudinal studies on the association between BP use and CRC risk A comprehensive literature search for articles published up to O ctober 2012 was performed. Prior to performing a meta‐analysis, the studies were evaluated for publication bias and heterogeneity. Relative risks ( RR s) or odds ratios were calculated. Six reports (four case–control studies and two cohort studies) published between 2010 and 2012 were identified. There was evidence of an association between any use of BP s and CRC risk using a fixed‐effects model ( RR = 0.80, 95% confidence interval = 0.74, 0.85) and a random‐effects model ( RR = 0.80, 95% confidence interval = 0.71, 0.90). However, we did not observe any evidence of a trend with increasing duration of use. Our findings indicate that there is evidence of an association between any use of BP and reduced CRC risk. However, this subject deserves further investigation.